Canaccord Genuity Reiterates Buy on Auxilium Pharma (AUXL)

By admin | 6 years ago

Auxilium Pharma (NASDAQ: AUXL)‘s stock had its “buy” rating reaffirmed by research analysts at Canaccord Genuity in a report released on Tuesday.

Shares of Auxilium Pharma traded down 0.95% during mid-day trading on Tuesday, hitting $18.80. Auxilium Pharma has a one year low of $13.59 and a one year high of $24.88. The company’s market cap is $908.1 million.

Auxilium Pharma last issued its quarterly earnings data on Thursday, May 10th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.11) by $0.07. The company’s quarterly revenue was up 26.0% on a year-over-year basis. On average, analysts predict that Auxilium Pharma will post $-0.06 earnings per share next quarter.

Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Auxilium Pharma in a research note to investors on Tuesday, May 15th. They now have a $20.00 price target on the stock. Separately, analysts at Oppenheimer (NYSE: OPY) reiterated a “market perform” rating on shares of Auxilium Pharma in a research note to investors on Friday, May 11st. Finally, analysts at MKM Partners cut their price target on shares of Auxilium Pharma to $20.00 in a research note to investors on Thursday, May 10th.

Auxilium Pharmaceuticals, Inc. ( Auxilium) is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists.

About the author